Search Results

You are looking at 1 - 10 of 119 items for :

  • "SEER Medicare" x
  • Refine by Access: All x
Clear All
Full access

Mary Katherine Montes de Oca, Lauren E. Wilson, Rebecca A. Previs, Anjali Gupta, Ashwini Joshi, Bin Huang, Maria Pisu, Margaret Liang, Kevin C. Ward, Maria J. Schymura, Andrew Berchuck, and Tomi F. Akinyemiju

. This study evaluated the association of 3 HCA dimensions measurable in the SEER-Medicare linked database (affordability, availability, and accessibility) in relation to racial/ethnic disparities in receipt of guideline-concordant treatment of OC

Full access

Firas Abdollah, Jesse D. Sammon, Kaustav Majumder, Gally Reznor, Giorgio Gandaglia, Akshay Sood, Nathanael Hevelone, Adam S. Kibel, Paul L. Nguyen, Toni K. Choueiri, Kathy J. Selvaggi, Mani Menon, and Quoc-Dien Trinh

. 20 The Charlson comorbidity index (CCI) was derived from the Medicare claims 1 year before PCa diagnosis using a previously validated algorithm. 21 Metropolitan areas were defined using the “Urban/Rural recode” field provided by SEER-Medicare

Full access

En Cheng, Peiyin Hung, and Shi-Yi Wang

characteristics, and comorbidities were associated with survival among patients with HCC. Methods Data Source and Population We established a population-based retrospective cohort study using the SEER-Medicare linked database. The SEER program is an authoritative

Full access

Anne A. Eaton, Camelia S. Sima, and Katherine S. Panageas

between off-label use in agreement with NCCN Guidelines versus off-label use without scientific support (ie, not included in NCCN Guidelines). Methods Data Source and Cohort Definition The SEER-Medicare linked database (including cancer

Full access

Amit D. Raval, Suresh Madhavan, Malcolm D. Mattes, Mohamad Salkini, and Usha Sambamoorthi

, and t 3 represented the precancer period and t 4 , t 5 , and t 6 represented the postcancer period ( Figure 1 ). Data Sources SEER-Medicare Linked Data: We used the NCI's SEER cancer registries data linked with Medicare administrative claims

Full access

En Cheng, Peiyin Hung, and Shi-Yi Wang

of HCC, it is critical to investigate geographic variations in HCC curative treatments and their associations with survival among HCC patients. Methods: Analyzing the Surveillance, Epidemiology, and End Results (SEER)-Medicare database, we

Full access

Stephanie Lakritz, Anna Schreiber, Elizabeth Molina, Elisabeth Meyer, Cathy J Bradley, and Jennifer R Diamond

-positive TNBC remain to be explored. Methods : Using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database, we identified 1,106 women with node-positive, TNBC diagnosed at age > 65 between 2010-2015. We compared patient and clinical

Full access

Sarguni Singh, Megan Eguchi, Sung-Joon Min, and Stacy Fischer

the SEER-Medicare database. The SEER program collects data from select cancer registries covering approximately 28% of the US population; 93% of persons aged ≥65 years in the SEER files are matched to the Medicare enrollment file. During our study, 72

Full access

Siyang Leng, Yizhen Chen, Wei-Yann Tsai, Divaya Bhutani, Grace C. Hillyer, Emerson Lim, Melissa K. Accordino, Jason D. Wright, Dawn L. Hershman, Suzanne Lentzsch, and Alfred I. Neugut

with a change in survival on a population level. Methods Data Source This retrospective cohort study used data from the SEER-Medicare database. 13 SEER is a population-based tumor registry developed by the NCI that captures time of diagnosis

Full access

Ami Vyas, S. Suresh Madhavan, Usha Sambamoorthi, Xiaoyun (Lucy) Pan, Michael Regier, Hannah Hazard, and Sita Kalidindi

.6 billion USD in the SEER-Medicare population, of which female breast cancer (BC) constituted the highest proportion at 13% ($16.5 billion). Further, it is projected to increase by 32% in 2020, presenting a significant burden to Medicare. 1 Of the $16